What Is a GLP-1?

GLP-1 stands for glucagon-like peptide-1. It's an incretin — a hormone released by the gut in response to food.

Specialized cells in the lining of the small intestine and colon, called L-cells, release GLP-1 within minutes of eating. It travels through the bloodstream and binds to GLP-1 receptors, which are found in the pancreas, the stomach, the heart, blood vessels, and several regions of the brain involved in appetite and reward.

Once it binds to those receptors, GLP-1 does four well-documented things:

1. It prompts the pancreas to release insulin — but only when blood sugar is elevated. This glucose-dependence is important. GLP-1 doesn't force insulin release when blood sugar is already normal, which is why the hormone itself carries a low risk of hypoglycemia.
2. It suppresses glucagon.Glucagon is insulin's counterpart; it tells the liver to release stored glucose. GLP-1 dials that signal down after a meal, when it isn't needed.
3. It slows gastric emptying. Food leaves the stomach more slowly, which blunts the post-meal blood sugar spike and prolongs the sensation of fullness.
4. It acts on appetite centers in the brain.GLP-1 receptors in the hypothalamus and brainstem contribute to satiety — the signal that you've had enough.

Together these effects explain why GLP-1 sits at the intersection of blood sugar control and appetite regulation. It is, in essence, one of the body's post-meal “that's enough” signals.

If GLP-1 works this well, why not simply administer it as a drug?

Because it disappears almost immediately. Native GLP-1 is broken down by an enzyme called DPP-4 (dipeptidyl peptidase-4) within a few minutes of entering the bloodstream. Its half-life is measured in minutes, not hours. As a therapy, it would require continuous infusion to have any sustained effect.

This is the problem that pharmaceutical development spent roughly two decades solving.

The medications people call “GLP-1s” are more precisely GLP-1 receptor agonists — molecules engineered to activate the same receptor as the natural hormone while resisting rapid breakdown.

Different drugs achieve this in different ways: modifying the peptide's amino acid sequence so DPP-4 can't cleave it, attaching fatty acid chains that bind to albumin in the blood and slow clearance, or — most recently — abandoning the peptide structure altogether in favor of a small molecule that survives digestion.

The result is a class of drugs that produce the same receptor signaling as GLP-1, but over days rather than minutes.

Two of these deserve a clarifying note.

Tirzepatide is not a pure GLP-1 agonist.It activates both the GLP-1 receptor and the GIP receptor — GIP being the other major incretin hormone. It's commonly grouped with GLP-1s in conversation, and the shorthand is understandable, but mechanistically it's a dual agonist.

Orforglipron is not a peptide.Approved in April 2026, it is the first small-molecule GLP-1 receptor agonist approved for weight management. Because it isn't a peptide, it survives digestion without the absorption workarounds that oral semaglutide requires.

A distinction worth keeping straight: several of these drugs share an active ingredient across two brand names with different approved uses and different maximum doses. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. The labeled indication, not the molecule, is what determines approved use and typically what determines insurance coverage.

The trial data for this class is unusually large and consistent. A few well-established findings:

Weight reduction. In its pivotal weight-management trial, semaglutide 2.4 mg produced roughly 15% mean body weight reduction over 68 weeks, compared with about 2.4% on placebo. Tirzepatide at its highest dose produced approximately 21% mean reduction over 72 weeks. Oral semaglutide 25 mg demonstrated 16.6% mean weight loss over 64 weeks among participants who adhered to treatment, with one in three losing 20% or more. Orforglipron delivered an average of 12.4% in its pivotal program. Individual results vary substantially around these averages.

Blood sugar control. GLP-1 receptor agonists meaningfully lower HbA1c in type 2 diabetes, which is the indication most of them were originally approved for.

Cardiovascular outcomes. In the SELECT trial, which enrolled more than 17,000 adults with overweight or obesity and established cardiovascular disease but not diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo (6.5% versus 8.0% over roughly 40 months). This supports a cardiovascular risk-reduction indication for Wegovy.

Liver disease. In August 2025, semaglutide 2.4 mg received accelerated approval for noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis, based on the ESSENCE trial. Accelerated approval means the finding rests on a surrogate endpoint — improvement in liver histology — with a confirmatory trial ongoing.

The most common adverse effects across this class are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. These are typically most pronounced during dose escalation and often diminish over time, which is why prescribers titrate doses gradually rather than starting at a therapeutic dose.

Less common but more serious risks documented in labeling include pancreatitis, gallbladder disease, kidney injury secondary to dehydration from vomiting or diarrhea, and — when combined with insulin or sulfonylureas — hypoglycemia.

Boxed warning. Most drugs in this class carry a boxed warning regarding thyroid C-cell tumors, based on findings in rodent studies. Whether this translates to human risk has not been established. Regardless, these medications are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

They are also not appropriate during pregnancy or while trying to conceive, and are not recommended in combination with one another.

This is an abbreviated summary, not a complete safety profile. Full prescribing information for any specific product is available through the FDA and the manufacturer, and the relevant risks for any individual are a conversation for a licensed clinician.

This is one of the most consistently misunderstood aspects of the class, and the evidence is clear enough to state plainly.

Obesity and type 2 diabetes are chronic conditions, and GLP-1 receptor agonists treat them as such. In a follow-up study of participants who stopped semaglutide after 68 weeks, roughly two-thirds of the lost weight was regained within the following year, and cardiometabolic improvements largely reverted alongside it.

The practical implication is that these are generally long-term therapies, not short courses. Anyone considering starting one should factor in what continuation — clinically and financially — actually looks like.

During the 2022–2024 supply shortages, compounding pharmacies were permitted to produce versions of semaglutide and tirzepatide. The FDA subsequently determined those shortages resolved — tirzepatide in December 2024 and semaglutide in February 2025 — which removed the legal basis for large-scale compounding of copies. In April 2026, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would further narrow the remaining pathways.

The important consumer-facing fact is simple and has not changed: compounded drugs are not FDA-approved. They are not reviewed by the FDA for safety, effectiveness, or manufacturing quality before they reach patients. That does not make them categorically unsafe, but it does mean the assurances that accompany an approved product do not apply.

A GLP-1 is a gut hormone that coordinates insulin release, glucagon suppression, gastric emptying, and appetite. GLP-1 receptor agonists are medications engineered to activate that same pathway for days at a time rather than minutes.

They are prescription drugs with a substantial and growing evidence base, real and well-documented side effects, specific contraindications, and outcomes that depend on continued use. They work best alongside dietary change and physical activity — which is not a disclaimer added for form, but a condition of the trials that produced the results above.

Whether one is appropriate for a given person depends on their medical history, current medications, and goals, and that determination belongs with a licensed clinician.